Form D · Biotechnology
X-Sight Inc
Cambridge, MA · CIK 0001965249
Offering snapshot reported Feb 27, 2023 · SEC filing
- Reported sold
- $130K Offering amount: $130K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 13, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 27, 2023 | Initial | $130,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-474302
Source: Form D, filed Feb 27, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Akintunde Akinwande | Director |
| Winston Chern | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
492 B Cambridge Sreet
Cambridge, MA, 02141
Cambridge, MA, 02141